Related Experiment Video
Updated: Feb 13, 2026

Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
Published on: January 20, 2022
Safety and efficacy of cerebral protection devices in transcatheter aortic valve replacement: A clinical end-points
Divyanshu Mohananey1, Kesavan Sankaramangalam1, Arnav Kumar2
1Department of Cardiovascular Medicine, Cleveland Clinic, OH, United States.
Insights
Cerebral protection devices (CPD) show a reduced risk of stroke within one week after transcatheter aortic valve replacement (TAVR). However, these devices do not significantly impact the primary composite outcome of stroke and mortality at 30 days.
Area of Science:
- Cardiology
- Neurology
- Medical Devices
Background:
- Stroke is a significant complication of transcatheter aortic valve replacement (TAVR), occurring in 4-11% of patients.
- Cerebral protection devices (CPD) are designed to mitigate cerebrovascular events during TAVR.
- While imaging studies suggest CPD reduce lesion volume, their clinical benefit remains unclear.
Purpose of the Study:
- To evaluate the clinical safety and efficacy of cerebral protection devices (CPD) in transcatheter aortic valve replacement (TAVR).
- To synthesize data from prospective randomized and non-randomized studies using meta-analysis techniques.
Main Methods:
- Meta-analysis of prospective randomized and non-randomized studies.
- Data summarized using Mantel-Haenszel relative risk (RR) and 95% confidence intervals (CI).
- Heterogeneity assessed using Higgins' I² statistic.
Main Results:
- No significant difference in the primary composite outcome of stroke and mortality at 30 days between CPD and no-CPD groups (RR 0.70; 95% CI 0.40-1.21).
- Comparable rates for peri-procedural strokes, 30-day stroke, mortality, AKI, major bleeding, life-threatening bleeding, and major vascular complications.
- A statistically significant reduction in the risk of strokes within the first week post-TAVR was observed in the CPD group (RR 0.56; 95% CI 0.33-0.96).
Conclusions:
- Cerebral protection devices (CPD) are associated with a decreased incidence of strokes within one week following TAVR.
- CPD do not increase the risk of other peri-procedural adverse events.
- The clinical utility of CPD in TAVR warrants further investigation despite the observed reduction in early stroke risk.
Background:
Stroke after transcatheter aortic valve replacement (TAVR) occurs with an incidence of 4-11% and is a particularly devastating adverse event associated with the procedure. Several cerebral protection devices (CPD) have been developed to prevent cerebrovascular events during TAVR. While most studies have shown CPD to be associated with decreased number and volume of lesions on diffusion weighted magnetic resonance imaging, the clinical benefit of these devices remains uncertain.
Methods:
We aimed to use meta-analysis techniques to study the clinical safety and efficacy of these CPD in prospective randomized and non-randomized studies. Data was summarized as Mantel-Haenszel relative risk (RR) and 95% confidence intervals (CI). We used the Higgins' I2 statistic to evaluate heterogeneity.
Results:
We found no evidence of difference between patients with and without CPD [RR 0.70 (95% CI 0.40-1.21)] for the primary composite outcome of stroke and mortality at 30 days. The two groups were also comparable in peri-procedural strokes [RR 0.53 (95% CI 0.27-1.07)], stroke at 30 days [RR 0.69(95% CI 0.38-1.26)], mortality [RR 0.59 (95% CI 0.22-1.59) at 30 days, AKI [RR 0.68(95% CI 0.28-1.62)], major bleeding [RR 0.56 (95% CI 0.26-1.18)], life threating bleeding [0.54 (95% CI 0.19-1.53)] and major vascular complications [RR 0.80 (95% CI 0.52-1.24)]. The risk of strokes within the first week of TAVR was significantly lower in the CPD group [0.56(95% CI 0.33-0.96)].
Conclusion:
CPD are associated with a decreased incidence of strokes within 1 week of follow-up without showing any evidence of increased risk of other peri-procedural adverse events.
More Related Videos
06:59Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation
Published on: June 3, 2018
14:14Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
Related Concept Videos
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Survey Safety
Self-Efficacy
Heart Valves
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
Directing Effect of Substituents: meta-Directing Groups
Statistical Software for Data Analysis and Clinical Trials